Rho-associated coiled-coil protein kinase (ROCK) inhibitors, have shown significant therapeutic potential for a wide range of ocular and non-ocular diseases. This includes new treatments for corneal endothelial disease, glaucoma, cardiovascular disease (Fasudil), neuronal disease, certain types of cancer, pulmonary diseases, erectile dysfunction and gastrointestinal diseases.
Sign up to keep reading
Create a free Member account at NZ Optics to read this article and more.
- Read all Member articles
- Full digital magazine archive
- Early access to new articles
